2 November 2026
Swissmedic: Additional Information on the Guidance Document “Import of a Human Medicinal Product according to Art. 14 para. 2 and 3 TPA (Parallel Import)”
Swissmedic has issued additional information on its guidance document on parallel imports under art. 14 para. 2 and 3 of the Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA). As part of the update of the guidance document of 1 October 2026, section 5.5.1 explicitly clarifies that affixing additional labels to existing foreign primary packaging is not accepted. This applies in particular to labels providing translations into the official Swiss languages, irrespective of the format and material of the primary packaging or the area to be covered.
A transitional rule applies to parallel imported medicinal products already authorised with approved additional labels on the primary packaging. An application for variation to remove the labels must be submitted within one year of publication of the communication. Batches already released are not affected and may continue to be placed on the market and sold. New batches may continue to be released according to the currently approved primary packaging design until the variation procedure is completed. Swissmedic recommends that affected marketing authorisation holders plan the necessary changes and variations in good time.
For more information, see here.